Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Bevacizumab (Avastin) combined with low-dose chemotherapy slows ovarian cancer

A targeted cancer drug given with low-dose chemotherapy shrank ovarian tumors and slowed progression of ovarian cancer in patients with recurrent disease, according to research findings presented by Agustin Garcia, M.D., principal investigator of the study and Director of Breast Cancer Research at the Women's Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center.

16 May 2005

Disabling gene defuses rheumatoid arthritis in mice

Scientists studying mice have identified a gene that allows immune cells known as neutrophils to protect themselves from the inflammatory chemicals they secrete.

16 May 2005

Tarvacin equivalent plus Docetaxel inhibits breast tumor growth by 93%

Peregrine Pharmaceuticals, Inc., today announced that a research article titled "A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice" was published in the May 15 issue of Cancer Research.

16 May 2005

Vaccine candidate to treat nicotine addiction shows promise

Cytos Biotechnology AG has announced that its vaccine candidate CYT002-NicQb to treat nicotine addiction has achieved proof of efficacy.

16 May 2005

Anti-nicotine vaccine to help smokers is promising

Swiss researchers say they have had some encouraging results with an experimental anti-nicotine vaccine.

15 May 2005

NIAID has awarded 10 grants and 2 contracts totaling approximately $27 million to fund development of new therapeutics and vaccines against bioterrorism

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded 10 grants and 2 contracts totaling approximately $27 million to fund development of new therapeutics and vaccines against some of the most deadly agents of bioterrorism including anthrax, botulinum toxin, Ebola virus, pneumonic plague, smallpox and tularemia.

11 May 2005

Targeted Genetics announces new patent for Hyperlipidemia

Targeted Genetics Corporation announced today issuance of U.S. patent #6,887,463, entitled, "Methods and Compositions for Gene Therapy for the Treatment of Defects in Lipoprotein Metabolism."

11 May 2005

Discovery may pave way for immunotherapies for prostate cancer

Using a common chemotherapy agent, researchers at UCLA's Jonsson Cancer Center and the Department of Pathology and Laboratory Medicine found a way to move an important biomarker expressed in prostate cancer, shaking it loose from one location in a cell – where it could not be accessed by blood – to another, easier to target area.

11 May 2005

Broken bones may reduce risk of ovarian cancer

The pain and suffering of a broken bone may yield an unexpected benefit – a reduced risk of ovarian cancer.

10 May 2005

Discovery reveals how stem cells can be used to help repair acute spinal cord damage

A treatment derived from human embryonic stem cells improves mobility in rats with spinal cord injuries, providing the first physical evidence that the therapeutic use of these cells can help restore motor skills lost from acute spinal cord tissue damage.

10 May 2005

Vaccine against Alzheimer's disease may still be on the cards

A new, but modified, trial of an Alzheimer's vaccine has begun in the U.S. despite an earlier one being abandoned in 2002 due to safety concerns.

10 May 2005

Cytogen Corporation and Dowpharma collaborate to create a targeted oncology product designed to treat prostate and other cancers

Under the agreement, Dowpharma's proprietary MeO-DOTA bifunctional chelant technology will be used to radiolabel Cytogen's prostate-specific membrane antigen (PSMA) antibody with a therapeutic radionuclide. PSMA is a protein highly expressed on the surface of prostate cancer cells and the neovasculature of many solid tumors.

10 May 2005

Researchers test vaccine to prevent dangerous Staphylococcal infections

Vanderbilt University Medical Center infectious diseases researchers are launching a trial for a new vaccine against Staphylococcus aureus. The vaccine, if proven effective, could help curb the growing threat of methicillin-resistant Staphylococcus aureus (MRSA), an emerging organism rapidly spreading through close personal contact.

10 May 2005

Simple and efficient method for creation of novel protein functions in an existing protein scaffold

By designing a molecular bridge, scientists at the University of Illinois at Urbana-Champaign have forged a successful pathway through a complex ocean of barriers: They've changed the function of a protein using a co-evolution approach.

8 May 2005

Boostrix receives FDA approval as treatment for pertussis

GlaxoSmithKline today announced that its booster vaccine, Boostrix received approval from the United States (U.S.) Food and Drug Administration (FDA).

3 May 2005

Scientists use tobacco plants to create antibodies against tumor cells

Scientists at Jefferson Medical College are using tobacco plants to produce monoclonal antibodies – tiny guided protein missiles – that can target and hunt down cancer cells. The plants promise to provide a cheaper, faster method of producing anticancer antibodies, raising hopes that the technology can one day be used in humans.

3 May 2005

College freshies show weaker immune responses

Being a college freshie may have more ramifications than being lonely and missing Mum's cooking, according to a new study at Carnegie Mellon University in Pittsburgh which shows that first-year students had a weaker immune response to the flu shot than did other students, and confirms suspicions that going to college challenges both mind and body.

2 May 2005

Loneliness and social network appear to make independent contributions to immunity

A new study at Carnegie Mellon University in Pittsburgh confirms how college challenges both mind and body, by demonstrating that lonely first-year students mounted a weaker immune response to the flu shot than did other students. The study appears in the May issue of Health Psychology, which is published by the American Psychological Association (APA).

2 May 2005

Blocking the COX-1 enzyme might be the answer in ovarian cancer treatment

Researchers at Vanderbilt University Medical Center in a new report say that blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer.

2 May 2005

Blocking the COX-1 enzyme might prevent and treat the most common and fatal form of ovarian cancer

Blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer, researchers at Vanderbilt University Medical Center reported this week.

1 May 2005